(Q34430219)

2 August 2017

1 reference

title

Chemotherapy with irinotecan (CPT-11), a topoisomerase-I inhibitor, for refractory and relapsed non-Hodgkin's lymphoma (English)

1 reference

2 August 2017

1 reference

T Takagi

1

1 reference

2 August 2017

T Saotome

series ordinal

2

1 reference

2 August 2017

publication date

1 August 2001

1 reference

2 August 2017

1 reference

2 August 2017

volume

42

1 reference

2 August 2017

issue

4

1 reference

2 August 2017

page(s)

577-586

1 reference

Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F10428190109099317

EPOCH chemotherapy: toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190109099317

Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190109099317

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190109099317

Topoisomerase I inhibitors: review and update

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190109099317

Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190109099317

Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190109099317

Phase I Study and Pharmacokinetics of CPT-11 With 5-Day Continuous Infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190109099317

Effects of CPT-11 in combination with other anti-cancer agents in culture

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190109099317

An early phase II study of CPT-11: a new derivative of camptothecin, for the treatment of leukemia and lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190109099317

Treatment of adult T-cell leukaemia-lymphoma with irinotecan hydrochloride (CPT-11). CPT-11 Study Group on Hematological Malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190109099317

Combination phase I/II study of irinotecan hydrochloride (CPT-11) and carboplatin in relapsed or refractory non-Hodgkin's lymphoma. CPT-11/Lymphoma Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190109099317

Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190109099317

Phase II study of irinotecan plus cisplatin in patients with advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190109099317

Phase II study of irinotecan and cisplatin as first-line chemotherapy in advanced or recurrent cervical cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190109099317

10.3109/10428190109099317

21 January 2018

Identifiers

DOI

1 reference

2 August 2017

1 reference